Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

PURPOSE: Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Esserman, Laura J., Berry, Donald A., DeMichele, Angela, Carey, Lisa, Davis, Sarah E., Buxton, Meredith, Hudis, Cliff, Gray, Joe W., Perou, Charles, Yau, Christina, Livasy, Chad, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debasish, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunn-Yi, Giri, Dilip, van 't Veer, Laura, Hylton, Nola
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2012
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3434983/
https://ncbi.nlm.nih.gov/pubmed/22649152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.2779
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge